A5070330715- Hepatitis B Virus Studies
- Hepatitis Viruses Studies and Epidemiology
- Bacterial Infections and Vaccines
- Hepatitis C virus research
- Pneumonia and Respiratory Infections
- Platelet Disorders and Treatments
- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cervical Cancer and HPV Research
- Immunotherapy and Immune Responses
- Blood groups and transfusion
- RNA Interference and Gene Delivery
- Vaccine Coverage and Hesitancy
- Herpesvirus Infections and Treatments
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 Clinical Research Studies
- Inhalation and Respiratory Drug Delivery
- Microbial Inactivation Methods
- Immune responses and vaccinations
- Toxin Mechanisms and Immunotoxins
- Respiratory viral infections research
- Infective Endocarditis Diagnosis and Management
- Genital Health and Disease
- Pharmacogenetics and Drug Metabolism
Inovio Pharmaceuticals (United States)
2019-2023
AstraZeneca (United States)
2021-2022
National Patient Safety Foundation
2021
AstraZeneca (United Kingdom)
2021
AstraZeneca (Sweden)
2021
Optum (United States)
2020
Pfizer (United States)
2014-2016
Jean Brown Research
2016
Foothill Family Clinic
2016
Merck & Co., Inc., Rahway, NJ, USA (United States)
2009-2014
Small interfering (si) and short hairpin (sh) RNAs induce robust degradation of homologous mRNAs, making them a potent tool to achieve gene silencing in mammalian cells. Silencing by siRNAs is used widely because it considered highly specific for the targeted gene, although recent report suggests that siRNA also signaling through type I IFN system. When human embryonic kidney 293 (HEK293) or keratinocyte (HaCaT) cell lines primary dendritic cells macrophages were transfected with shRNAs,...
BackgroundWe report updated safety, efficacy, and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) from an ongoing phase 3 trial.MethodsAdults at increased risk SARS-CoV-2 infection were randomized (2:1), stratified by age, to receive 2 doses or placebo. The primary efficacy end point was confirmed reverse-transcriptase PCR-positive (RT-PCR-positive) symptomatic COVID-19 15 more days after a second dose in baseline SARS-CoV-2-seronegative participants. 21,634 10,816 participants placebo,...
RNA interference (RNAi) is a powerful method that specifically suppresses gene expression in sequence-dependent manner whose machinery found organisms from fungi to mammals. Mammalian cells have developed sequence-independent system of suppression often induced by viral replication includes the recognition double-stranded (dsRNA) through Toll-like receptor 3 (TLR3) and induction type I interferon synthesis. Interferon activates transcription set genes including dsRNA-activated protein kinase...
This study in healthy adolescents (11 to <18 years) evaluated coadministration of quadrivalent human papillomavirus vaccine (HPV-4), with bivalent rLP2086, a meningococcal serogroup B (MnB) vaccine.Subjects received rLP2086 + HPV-4, saline or HPV-4 at 0, 2 and 6 months. Immune responses antigens were assessed 1 month after doses 3. Serum bactericidal assays using complement (hSBAs) 4 MnB test strains expressing vaccine-heterologous factor H binding protein (fHBP) variants determined immune...
VGX-3100 is an investigational DNA-based immunotherapy being developed as alternative to surgery and ablation for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) with the aim of preserving reproductive health while treating precancerous disease. Response durability up 1.5 y following dosing now reported.Histologic regression HPV16 and/or HPV 18 (HPV16/18) clearance were previously demonstrated in a randomized, placebo-controlled, double-blind trial reported 6 months after last...
COVID-19 remains a significant risk for the immunocompromised given their lower responsiveness to vaccination or infection. Therefore, passive immunity through long-acting monoclonal antibodies (mAbs) offers needed approach pre-exposure prophylaxis (PrEP). Our study evaluated safety, anti-SARS-CoV-2 neutralizing activity, nasal penetration, and pharmacokinetics (PK) of two half-life-extended investigational mAbs, AER001 AER002, providing first demonstration upper airway penetration mAbs with...
Background: Bivalent rLP2086, targeting meningococcal serogroup B, will extend prevention of disease beyond that provided by quadrivalent ACWY vaccines; coadministration with recommended vaccines may improve adherence to vaccine schedules. This phase 2, randomized, active-controlled, observer-blinded study assessed whether immune responses induced Menactra (meningococcal A, C, Y and W-135 polysaccharide conjugate [MCV4]) Adacel (tetanus toxoid, reduced diphtheria acellular pertussis [Tdap])...
RNA interference (RNAi) is an antiviral mechanism that activated when double-stranded cleaved into fragments, called short interfering (siRNA), prime inducible gene silencing enzyme complex. We applied RNAi against a herpes simplex virus type 1 (HSV-1) gene, glycoprotein E, which mediates cell-to-cell spread and immune evasion. In in vitro model of infection, human keratinocytes were transfected with siRNA specific for E then infected wild-type HSV-1. RNAi-mediated reproduced the small...
Management of cervical high-grade squamous intraepithelial lesions (HSILs), the immediate precursor cancer, consists largely surgical treatment for women at higher risk progression to cancer. The authors' objective was describe occurrence HSIL in United States and various outcomes who received treatment.From a US commercial health insurer, cohort adult with diagnoses receiving within 3 months diagnosis between January 2008 September 2018 identified. This followed several outcomes, including...
The rat maternally transmitted Ag has been previously described as a minor histocompatibility composed of mitochondrially factor (MTF) and the RT1.Aa MHC class I molecule. We compared DNA sequences 13 mitochondrial open reading frames from different strains identified four coding polymorphisms that correlated with this MTF. used synthetic 17-mer peptides spanning to sensitize appropriate target cells in lymphocytotoxicity assays found MTF is derived an internal region ATPase 6. A...
Merck has developed a manufacturing process modification for RECOMBIVAX HB. Three lots of modified hepatitis B vaccine (mpHBV) were studied in randomized, blinded trial to demonstrate similarity the three mpHBV and noninferiority HB (control vaccine) with regard immunogenicity.Month 7 SPRs groups ranged from 97.8 98.9% (98.2% combined). The seroprotection rate (SPR) control group was 98.5%. estimated geometric mean titer (GMT) 1761 mIU/mL combined 1108 group. GMT ratio (mpHBV/control) 1.6...
Background: Combination diphtheria-tetanus-5 component acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (DTaP5-IPV-Hib-HepB) administered either concurrently with 7-valent pneumococcal conjugate (PCV7) or 1 month apart was generally safe and immunogenic at 2, 4 6 months of age. This study examined the effects a booster dose age 15 months. Methods: Participants were randomized to DTaP5-IPV-Hib-HepB plus PCV7, PCV7 later pentavalent...
Background: Generating protective immune responses in older adults (particularly ≥65 years) remains challenging for vaccines general. This study examined the response engendered by RECOMBIVAX HB™ manufactured using a modified adjuvant (modified-process hepatitis B vaccine; mpHBV), RECOMBIVAX-HB™, and ENGERIX-B™. Methods: Randomized, double-blind, multicenter enrolled healthy, seronegative subjects (N=538) to receive mpHBV (10 µg surface antigen [HBsAg]), RECOMBIVAX-HB™ HBsAg), or ENGERIX-B™...
Background: DTaP5-IPV-Hib-HepB, an investigational hexavalent combination vaccine, was evaluated for safety and immunogenicity, when administered to infants with heptavalent pneumococcal conjugate vaccine (PCV7). Methods: Infants were randomized receive DTaP5-IPV-Hib-HepB plus PCV7, PCV7 1 month later or DTaP5-IPV/Hib HepB at 2, 4 6 months of age in open-label, phase IIb trial. Vaccine responses assessed by pertussis toxoid, filamentous hemagglutinin, pertactin fimbriae types 2/3...
Abstract Rare cases of thrombosis with thrombocytopenia syndrome (TTS) have been reported after AZD1222. Anti-platelet factor-4 (PF4) antibodies were observed in patients following presentation TTS, however it is unclear if AZD1222 was responsible for inducing production anti-PF4. Paired samples (baseline and day-15) from a phase 3 trial vs placebo analyzed anti-PF4 levels; 19/1727 (1.1%, AZD1222) 7/857 (0.8%, placebo) participants anti-PF4-IgG-negative at baseline but had moderate Day-15...
HPV remains the most common sexually transmitted disease worldwide, despite improvements in awareness, screening, prophylactic vaccination uptake, and surgical treatment. VGX-3100 is an immunotherapy that uses electroporation to introduce DNA encoding for modified HPV-16 HPV-18, E6-and E7 proteins into myocytes stimulate effector T cell response. We now report immunogenicity safety of a refrigeration-stable formulation, which improves patient-care setting usability.This multi-arm,...
A modified process hepatitis B vaccine (mpHBV) uses higher phosphate content in the manufacturing relative to current product, Recombivax-HB. The is thought improve antigen presentation, and thereby, increase antibody production. mpHBV was previously shown be well tolerated immunogenic adults. study tested a 2-, 4-, 6-month vaccination schedule dose formulation (10 μg mpHBV) healthy infants.In randomized, double-blind study, infants (N = 1718), approximately 2 months of age, received 0.5-mL...